ArticleIJU case reports2026
Neuroendocrine Transformation Without PSA Elevation in High-Risk Metastatic Castration-Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration-sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate-specific antigen. Case Presentation: An 86-year-old male with severe acute renal failure demonstrated a prostate-specific antigen level of 306 ng/mL and a Gleason score of 4 + 5 on prostate biopsy. Imaging revealed lung, bone, and lymph node metastases, leading to a diagnosis of high-risk metastatic castration-sensitive prostate cancer. Abiraterone acetate was initiated immediately. Nineteen months later, multiple liver metastases were detected despite stable prostate-specific antigen levels. The patient died 4 months later. Autopsy revealed widespread metastases, all histologically confirmed as neuroendocrine prostate cancer. Conclusion: Strong androgen receptor suppression in metastatic castration-sensitive prostate cancer can lead to aggressive radiographic progression without prostate-specific antigen elevation, underscoring the limitations of antigen-based monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.